Announcing the 2023 HBA Global Board of Directors | HBA

Announcing the 2023 HBA Global Board of Directors

At today’s Healthcare Businesswomen's Association’s (HBA) Annual Business Meeting, the membership electorate voted on the board leadership that will ensure the organizational focus, strategies, and plans are aligned to accelerate HBA’s mission and support our vision.

We are proud to announce the 2023 HBA Global Board of Directors:

Executive Committee

  • Chair: Julie Ross | CEO and President, Advanced Clinical
  • Vice-Chair: Gisela Paulsen | COO and President, Oncocyte Corporation
  • Secretary/Treasurer: Carol Montandon | Global Chief Quality Officer and Worldwide VP, Quality and Compliance, Johnson & Johnson
  • HBA Chief Executive Officer: TBA (ex-officio, non-voting)

Directors at Large

  • Paula Bekinschtein | Founder and Managing Director, WalkBek Consulting
  • Adam Dubow | General Counsel, Day One Biopharmaceuticals
  • Deborah Gordon* | EVP, Chief Administrative Officer, and Chief Legal Officer, Memorial Hermann Health System
  • Teresa Graham | Head, Global Product Strategy, Roche Genentech
  • Nicola Greenway | SVP, Group Head of HR, Global Portfolio Division, Takeda Pharmaceutical Company
  • Sabine Hutchison* | CEO, Seuss+ (HBA EMEA Operating Board President)
  • Tamika Jean-Baptiste | VP and Chief Diversity Officer, Amgen Inc.
  • Nyawira Njeru | Director, Market Access and Strategic Partnerships-Middle East and Africa, Hologic Inc.
  • Miguel Serrano Kieckebusch | Healthcare Unicorn
  • Karima Sharif* | Head of Inclusive Investments and Partnerships Lead (HCP/DTC), Publicis Health Media (HBA North America Operating Board President)
  • Mary Stutts | Global Chief Inclusion and Health Equity Officer, Real Chemistry

The generous donation of time and talent from board members enables the HBA to keep our strategies fresh and relevant while maintaining a laser focus on the longer-term goal of gender equity at all levels of leadership.
The incoming directors are inspired with their charge to continue the great work of the 2022 Board, to champion HBA’s mission of furthering the advancement and impact of women in the business of healthcare.

Asterisks (*) indicate non-voting members.
We are also happy to announce the 2023 HBA Nominating Committee:

  • Chair, Shideh Bina | Founding Partner, Insigniam
  • Jocelyn Allen | Head, One Finance Experience, Sanofi  
  • Sheryl R. Fox | Founder and CEO, FutureHealth Strategies  
  • Erik D. Smith, PhD | Principal, Strategy and Analytics, Life Sciences, Deloitte LLP
  • Sean Yap | Founder, Phenotype  

As the new Board and Nominating Committee prepare for the year ahead, we also want to graciously thank the 2022 Global Board of Directors and Nominating Committee.

A special thank you to members completing their term of Board service:

2022 HBA Board Chair

  • Shideh Bina | Founding Partner, Insigniam

2022 Directors at Large

  • Jacquelyn Benton Moore | Healthcare Executive Director, Roche Genentech
  • Anita Burrell | Founder, Anita Burrell Consulting LLC
  • Laura Butler | CEO, WorkLife Consulting, LLC
  • Michelle Greene | Chief Information Officer, Cardinal Health
  • Michelle Keefe | CEO, Syneos Health
  • Keya Pitts, MPH | VP, Global Safety Operations, Global Patient Safety and Risk Management, Alnylam Pharmaceuticals, Inc.
  • Kathrin Schoenborn-Sobolewski | Investor and Start Up Advisor
  • Erik D. Smith, PhD | Principal, Strategy and Analytics, Life Sciences, Deloitte LLP
  • Jhaymee Tynan | Consultant, Health Practice, CFO, CHRO, and DEI Specialist, Egon Zehnder
  • Dianne Yurek | Market Access Innovation Strategy Leader, AstraZeneca

2022 Nominating Committee:

  • Chair: Rebecca Vermeulen | VP, Global Patient Networks, Product Development Medical Affairs , Roche

Committee Members

  • Ayanna Telfort | EVP, Director of Client Services, Razorfish Health
  • Tint Tint Yap | VP, Integration, Separation, and Transition, Bayer
Groups audience: 

Chat Provider: LiveChat